Navigation Links
Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in,Lamellar Ichthyosis

Drug Effectively Treated 41 to 50% of Patients and Was Well-Tolerated
PRINCETON, NJ, Jun 14, 2007 (MARKET WIRE via COMTEX News Network) -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company that develops and markets dermatology products, today announced results from its completed Phase 2/3 study of liarozole in lamellar ichthyosis, a rare genetic disorder (incidence of approximately 1 in 200,000) which is characterized by a thick scaling of the skin over large body areas. Study results showed liarozole, dosed at 75 mg and 150 mg per day for 12 weeks, was well-tolerated and "effectively treated" the disorder in 41% and 50% of the patients, respectively. The primary efficacy endpoint, "effectively treated," was defined as the percentage of patients that obtained at least a 2 point reduction in investigator's global assessment (IGA) score as defined on a 5 point scale.

The randomized, double-blind, placebo-controlled dose ranging study enrolled 64 patients in three treatment groups. Patients received placebo, 75 mg or 150 mg of liarozole daily for 12 weeks, randomized 1:3:3, respectively. Response rates for the primary endpoint were 41% (11 of 27 patients) for the 75 mg dose, 50% (14 of 28 patients) for the 150 mg dose and 11% (1 of 9 patients) for placebo. The p-values for the 75 and 150 mg per day groups compared to placebo were p=0.2193 and p=0.0557, respectively.

For the secondary endpoints of mean IGA score at week 8 and the overall scaling score at weeks 8 and 12, both liarozole groups achieved statistically significant differences from placebo (p < 0.05). The mean IGA score at week 8 was reduced by 36% and 43% for the 75 and 150 mg liarozole treatment groups, respectively versus 3% for placebo. The mean IGA score for the two liarozole treatment groups continued to improve through 12 weeks. The mean reduction in overall scaling was approximately 45% for both liarozole treatment
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:7/2/2015)... , June 25, 2015 ... of the "Veterinary / Animal Vaccines Market by ... report to their offering. The global ... by 2020 from $5,507.3 Million in 2015, at a ... Major factors fueling market growth are growing prevalence of ...
(Date:7/2/2015)... LONDON , July 2, 2015 ... commitment to improving access to HIV treatments   ... a strategic manufacturing agreement to enable production in ... additional source of the dolutegravir active pharmaceutical ingredient (API), and ... the finished product (dolutegravir 50mg, marketed under the name Tivicay®) ...
(Date:7/1/2015)... CENTENNIAL, Colo. , July 1, 2015 /PRNewswire/ ... leader in implantable hearing solutions, announced today the ... the Cochlear™ Nucleus® Profile™ Implant with Slim Straight ... experience and developed in close collaboration with the ... thinnest cochlear implant platform designed to provide the ...
Breaking Medicine Technology:Veterinary / Animal Vaccines Market 2015 - Global Forecast to 2020 for the $7.19 Billion Industry 2ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 2ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 3ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 4ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 5ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 6Cochlear Combines the World's Thinnest Cochlear Implant Platform with the Industry's Thinnest Full Length Electrode 2Cochlear Combines the World's Thinnest Cochlear Implant Platform with the Industry's Thinnest Full Length Electrode 3
... California, 23 May 2007 - The antidepressant duloxetine,hydrochloride ... patients who did not respond, or responded only,partially, ... regardless of whether those patients were,switched from an ... was presented today at the American Psychiatric,Association’s 160 ...
... - ImmunoGen, Inc.,(Nasdaq: IMGN), a biopharmaceutical company that ... today announced that clinical findings for three,different TAP ... to be,reported at the 43rd American Society of ... 1-5, 2007 in Chicago, IL., Trastuzumab-DM1 (abstract #1042) ...
Cached Medicine Technology:In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 2In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 3In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 4In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 5In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 6In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 7In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 8In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression 9ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 2ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 3
(Date:7/2/2015)... ... July 02, 2015 , ... “ LIFX ” was featured on NewsWatch as ... available to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted ... smart light bulbs on the market. , According to the U.S. Department of Energy, ...
(Date:7/2/2015)... ... July 02, 2015 , ... The ZAC Foundation, a national leader ... with important lessons on how to stay water safe with the help of a ... authored by The ZAC Foundation co-founders, follows Zeke’s water safety journey. Zeke, who ...
(Date:7/2/2015)... Pennsylvania (PRWEB) , ... July ... ... largest e-commerce janitorial supply company , announced today that it has ... Products. The acquisition will make CleanItSupply.com the largest distributor of Rubbermaid Commercial ...
(Date:7/2/2015)... ... 02, 2015 , ... Scientists at the University of ... five federal grants to study a group of related mosquito-borne viruses. The ultimate ... The research will be conducted in the Regional Biocontainment Laboratory (RBL) at Pitt, ...
(Date:7/2/2015)... ... July 02, 2015 , ... B. E. Smith, the ... to lead a national chief operating officer recruitment for Nicklaus Children’s ... healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare executives ...
Breaking Medicine News(10 mins):Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 2Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 3Health News:CleanItSupply.com Acquires eRubbermaid.com 2Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 2Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 3Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 4Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 2Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 3
... 6, 2008) -- Weill Cornell Medical College has been awarded ... Abuse Case Coordination and Review Center (EACCRC), in collaboration with ... at the Hebrew Home at Riverdale and the New York ... & Leslie R. Samuels Foundation, with matching funds from a ...
... alleviate the plaguing symptoms of allergies ... and asthma, ... allergies or asthma while outdoors, but why deal with irritating,triggers in your home? ... focus on more important things, not on your,symptoms., Try to prevent as ...
... discuss IRCO,s Neighborhood Reconstruction Program to normalize up, to 600,000 internally ... ... neighborhoods, WASHINGTON, May 6 Dr. Said Hakki, president,of ... and available for interviews to discuss the organization,s,Neighborhood Reconstruction Program (NRP) ...
... 2008: Some of the UKs leading experts in location ... in hospitals are already improving the efficiency and quality ... problems between hardware and software applications, and a lack ... the NHS is not benefiting as much as it ...
... 6 VirtualCDO acted as the M&A,advisor to ... company to Lawson,Software (St. Paul, MN). VasTech is ... healthcare, hospitality and government,service companies in the U.S. ... services to some 4,000 customers across,40 countries., ...
... Recognize Patients, Safety,Concerns, But Lack Confidence About Best ... 6 As patient safety,incidents in America,s hospitals ... few hospital CEOs feel strongly confident about practices ... response, the VHA Foundation,today formally launched the "Health ...
Cached Medicine News:Health News:Weill Cornell receives funding to study creation of new elder abuse center 2Health News:Double Trouble: Fight Allergy and Asthma in Your Home 2Health News:Dr. Said Hakki, President of Iraqi Red Crescent Organization, in the United States and Available for Interviews May 12-16 2Health News:Dr. Said Hakki, President of Iraqi Red Crescent Organization, in the United States and Available for Interviews May 12-16 3Health News:Location! Location! Location technologies are improving NHS care 2Health News:VirtualCDO Acts as M&A Advisor in Sale of VasTech to Lawson Software 2Health News:VHA Foundation Launches National CEO Patient SafetyNetwork, Starting From the Top to Make Patients Safer 2Health News:VHA Foundation Launches National CEO Patient SafetyNetwork, Starting From the Top to Make Patients Safer 3
The Surgiflex WAVE is a comfortable, easy to use, versatile, and interchangeable suction-irrigation device....
... Clinicians are demanding smaller, higher performing ... clinical and operational challenges. The new ... powerful architecture for superb High Definition ... and ease-of-use; and a versatile suite ...
The Cardiff Acuity Test is designed specifically for,acuity measurement in children aged 1 to 3 years. The,test is also helpful with other age groups with,intellectual impairment, dementia, hea...
... InfinixTM CF-i/SP brings revolutionary flexibility to ... enables operators to move the C-arm ... to obtain the optimal angle for ... features an 8-inch cardiac flat panel ...
Medicine Products: